Selected article for: "SARS vitro efficacy and vitro efficacy"
Author: Ahidjo, Bintou A.; Loe, Marcus Wing Choy; Ng, Yan Ling; Mok, Chee Keng; Chu, Justin Jang Hann
Title: Current Perspective of Antiviral Strategies against COVID-19
  • Cord-id: hfvw575w
  • Document date: 2020_6_2
    • ID: hfvw575w
    Snippet: [Image: see text] COVID-19 was declared a pandemic by the World Health Organization on March 11, 2020. This novel coronavirus disease, caused by the SARS-CoV-2 virus, has resulted in severe and unprecedented social and economic disruptions globally. Since the discovery of COVID-19 in December 2019, numerous antivirals have been tested for efficacy against SARS-CoV-2 in vitro and also clinically to treat this disease. This review article discusses the main antiviral strategies currently employed
    Document: [Image: see text] COVID-19 was declared a pandemic by the World Health Organization on March 11, 2020. This novel coronavirus disease, caused by the SARS-CoV-2 virus, has resulted in severe and unprecedented social and economic disruptions globally. Since the discovery of COVID-19 in December 2019, numerous antivirals have been tested for efficacy against SARS-CoV-2 in vitro and also clinically to treat this disease. This review article discusses the main antiviral strategies currently employed and summarizes reported in vitro and in vivo efficacies of key antiviral compounds in use.

    Search related documents:
    Co phrase search for related documents
    • accessory structural and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
    • accessory structural protein and acute sars cov respiratory syndrome coronavirus: 1, 2
    • action potential mechanism and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7
    • action potential mechanism and lopinavir ritonavir: 1
    • activity antiviral property and acute sars cov respiratory syndrome coronavirus: 1
    • acute sars cov respiratory syndrome coronavirus and adamantane derivative: 1
    • acute sars cov respiratory syndrome coronavirus and additional mechanism: 1, 2, 3, 4, 5
    • acute sars cov respiratory syndrome coronavirus and adenosine analogue: 1, 2, 3
    • acute sars cov respiratory syndrome coronavirus and long period: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute sars cov respiratory syndrome coronavirus and lopinavir nelfinavir: 1, 2, 3, 4
    • acute sars cov respiratory syndrome coronavirus and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute sars cov respiratory syndrome coronavirus and lopinavir ritonavir efficacy: 1, 2, 3, 4, 5, 6, 7
    • additional mechanism and lopinavir ritonavir: 1
    • adenosine analogue and lopinavir ritonavir: 1, 2, 3